Literature DB >> 14751577

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.

Rosemary A Hannon1, Jackie A Clowes, Alison C Eagleton, Amna Al Hadari, Richard Eastell, Aubrey Blumsohn.   

Abstract

Previous immunoassays developed for the measurement of serum tartrate-resistant acid phosphatase (TRACP) have lacked specificity for osteoclastic TRACP, TRACP 5b, or have not shown satisfactory clinical performance. The aim of this study was to evaluate the clinical performance of a novel immunocapture activity assay for TRACP 5b, in comparison to telopeptide fragments of type I collagen. Within-subject variability and the effect of feeding on TRACP 5b and telopeptides of type I collagen were assessed in 20 healthy premenopausal women. Diurnal variation of TRACP 5b and serum beta C-terminal cross-linked telopeptide of type I collagen (sbetaCTX) was assessed in 12 healthy postmenopausal women. Renal clearance was assessed in 19 end stage renal failure patients undergoing routine haemodialysis. Response to antiresorptive treatment and calcium supplementation was assessed in osteoporotic postmenopausal women treated with alendronate and calcium (n = 16) or with calcium alone (n = 7) for 24 weeks.Within-subject variability (CVi) of TRACP 5b was 6.6%, lower than CVi of urinary and serum telopeptides. TRACP 5b decreased by 2.4 +/- 0.8%, in response to feeding (P < 0.05) compared to 7.0 +/- 2.6% to 7.9 +/- 3.7% for urinary telopeptides (P < 0.05 to < 0.01) and 8.5 +/- 1.7% to 17.8 +/- 2.6% for serum telopeptides (P < 0.0001). The amplitude of the diurnal rhythm for TRACP 5b was small compared to that of sbetaCTX, 14 +/- 4% vs. 137 +/- 14%. Haemodialysis did not have a significant effect on TRACP 5b but reduced sbetaCTX by 46 +/- 4% (P < 0.0001). In response to alendronate, TRACP 5b decreased by 39 +/- 4% compared to 49 +/- 4% to 69 +/- 5% for urinary telopeptides and 75 +/- 8% for sbetaCTX. We conclude that TRACP 5b shows an attenuated response to antiresorptive therapy in comparison with other markers of bone resorption, but that this may be offset by lower biological variability. TRACP 5b may provide useful additional information about bone resorption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751577     DOI: 10.1016/j.bone.2003.04.002

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  32 in total

Review 1.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

2.  Improved methods for testing antiresorptive compounds in human osteoclast cultures.

Authors:  Jukka P Rissanen; Hannele Ylipahkala; Katja M Fagerlund; Clive Long; H Kalervo Väänänen; Jussi M Halleen
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

3.  Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.

Authors:  B K D Sarvari; D Sankara Mahadev; S Rupa; S A Mastan
Journal:  Indian J Clin Biochem       Date:  2013-11-20

Review 4.  Bone markers in osteoporosis.

Authors:  Patrick Garnero
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

5.  Bone: reference bone turnover markers-just a fairy tale?

Authors:  Markus J Seibel
Journal:  Nat Rev Endocrinol       Date:  2011-07-26       Impact factor: 43.330

6.  The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study.

Authors:  Shinichi Nakatoh
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

7.  A mineral-rich extract from the red marine algae Lithothamnion calcareum preserves bone structure and function in female mice on a Western-style diet.

Authors:  Muhammad Nadeem Aslam; Jaclynn M Kreider; Tejaswi Paruchuri; Narasimharao Bhagavathula; Marissa DaSilva; Ronald F Zernicke; Steven A Goldstein; James Varani
Journal:  Calcif Tissue Int       Date:  2010-02-24       Impact factor: 4.333

8.  Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.

Authors:  Christian Bieglmayer; Hans Peter Dimai; Rudolf Wolfgang Gasser; Stefan Kudlacek; Barbara Obermayer-Pietsch; Wolfgang Woloszczuk; Elisabeth Zwettler; Andrea Griesmacher
Journal:  Wien Med Wochenschr       Date:  2012-08-14

9.  Preservation of bone structure and function by Lithothamnion sp. derived minerals.

Authors:  Muhammad Nadeem Aslam; Ingrid Bergin; Karl Jepsen; Jaclynn M Kreider; Kristin H Graf; Madhav Naik; Steven A Goldstein; James Varani
Journal:  Biol Trace Elem Res       Date:  2013-10-06       Impact factor: 3.738

10.  Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects.

Authors:  Yoshiki Nishizawa; Masaaki Inaba; Mitsukazu Ishii; Hiroyuki Yamashita; Takami Miki; Hitoshi Goto; Sinsuke Yamada; Osamu Chaki; Kentaro Kurasawa; Yoshiko Mochizuki
Journal:  J Bone Miner Metab       Date:  2008-05-11       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.